Abstract | BACKGROUND: CASE REPORTS: CONCLUSIONS: Before chemotherapy appropriate prophylaxis for HBV reactivation should always be administered to at-risk patients. However, if reactivation with FLF occurs, OLT should not be generally denied. The prognosis of the hematologic malignancy should be assessed; OLT should be considered for patients in remission with a favorable long-term prognosis, for our data suggest acceptable survival.
|
Authors | J Sperl, S Frankova, E Kieslichova, M Oliverius, L Janousek, E Honsova, P Trunecka, J Spicak |
Journal | Transplantation proceedings
(Transplant Proc)
Vol. 45
Issue 7
Pg. 2834-7
(Sep 2013)
ISSN: 1873-2623 [Electronic] United States |
PMID | 24034061
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 Elsevier Inc. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- DNA, Viral
|
Topics |
- Adult
- Antineoplastic Agents
(adverse effects)
- DNA, Viral
(analysis)
- Female
- Hepatitis B virus
(drug effects, genetics, physiology)
- Humans
- Liver Transplantation
- Lymphoma
(drug therapy)
- Male
- Middle Aged
- Retrospective Studies
- Virus Activation
|